Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ctDNA as a Predictive Marker for Early Switch in Treatment for Metastatic Breast Cancer
NCT05826964Phase 2Active, not recruiting
- Sponsor
- University of Miami
- Start
- Jun 2023
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fulvestrant in breast cancer (4 arms), sponsored by University of Miami. Primary endpoint: Progression-Free Survival 1 up to 36 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05826964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826964.